drugset / Trial / NCT04060316

GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery

NCT04060316

Phase 2 Unknown 99 enrolled GeneOne Life Science, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This clinical trial will evaluate the safety, tolerability and effectiveness of GLS-1200 nasal spray in addition to the standard of care after endoscopic sinus surgery in people with chronic sinusitis.

Timeline

Start
2023-12
Primary completion
2023-12
Completion
2024-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Quinine Small molecule 1 mg/ml Intranasal